Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent for reducing adverse side effects of kinase inhibitor

A technology of kinase inhibitors and side effects, applied in the field of anticancer drugs, can solve the problems of side effects and serious anticancer drugs

Active Publication Date: 2014-09-03
EA PHARMA CO LTD +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] On the other hand, many anticancer agents have serious side effects, and depending on the symptoms and severity of the side effects, administration may have to be discontinued.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for reducing adverse side effects of kinase inhibitor
  • Agent for reducing adverse side effects of kinase inhibitor
  • Agent for reducing adverse side effects of kinase inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0181] The CDAA (choline deficient amino acid supplementation) diet was used to induce liver cancer model rats, and the effect of co-administration of sorafenib and branched-chain amino acids (BCAA) was studied. As the CDAA diet, a commercially available choline-deficient diet (? 518753: Choline Deficient and iron Supplemented L-Amino Acid Defined Rat Diet, manufactured by Dyets) was used. .

[0182] Six-week-old Fischer 344 rats were divided into a CDAA dietary intake group, a sorafenib single intake group, and a BCAA combined intake group (each group: N=15), and were given the experimental diet freely. As an experimental diet, only the CDAA diet was provided to the CDAA diet intake group. For the sorafenib alone intake group, the sorafenib toluenesulfonate was mixed in the CDAA diet so that the intake of sorafenib per unit weight was 16mg / kg / day (800mg / 50kg / day). Sorafenib tablets (200 mg of Nexaball (registered trademark) tablets, manufactured by Bayer Pharmaceutical Co.,...

Embodiment 2

[0188] (inhibition of cell proliferation)

[0189] Huh7 cells were divided into 6×10 3 Cells / wells were seeded into 96-well plates, replaced with LC (containing 10% FBS) medium the next day, and 2 mM BCAA was added to Sorafenib at a concentration of 0, 1, 2, 4, and 8 μM, Incubation was carried out for 48 hours. In addition, the case of culturing for 48 hours without adding BCAA was used as a control.

[0190] After 48 hours, the medium was removed and 4% paraformaldehyde was added to the wells and fixed for 15 minutes. After removal of paraformaldehyde, 5% Hoechst solution was added to each well and left for 1 min. After removing the 5% Hoechst solution, 200 μl of PBS solution was added to each well.

[0191] The number of cells on this plate was analyzed by array scan, and the number of cells in each group was calculated as the percentage of proliferation (% of proliferation) when the control (LC10%) was set to 100. The results are shown in figure 2 .

[0192] Depend ...

Embodiment 3

[0194] (anti-tumor effect enhancing effect)

[0195] Huh7 cells in 1x10 7 Cells / mouse were subcutaneously transplanted into BALB / c nude mice.

[0196] After 1 week, they were grouped by tumor diameter, and 5 mg / kg Sorafenib was administered orally for 2 weeks (5 days / week of Sorafenib administration). Feed supply containing 3% BCAA.

[0197] The third week of administration is to increase the dosage of Sorafenib from 5mg / kg to 30mg / kg, and administer it orally for 5 days. Meanwhile, the feed containing 3% BCAA was continuously supplied.

[0198] The tumor diameter of each group was measured from the start of administration to 3 weeks after, and the mean value + SE of the tumor volume was calculated. The tumor volume is based on the long diameter of the tumor / 2x (short diameter) 2 to figure it out.

[0199] The results are shown in image 3 .

[0200] Depend on image 3 From the results, it can be clearly seen that in the sorafenib + BCAA group, the degree of reduction ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an agent for reducing the side effects of kinase inhibitors, the agent containing at least one branched-chain amino acid selected from among isoleucine, leucine and valine or a salt thereof as an active ingredient, and also relates to an anticancer medicine containing at least one branched-chain amino acid selected from among isoleucine, leucine and valine or a salt thereof, and a kinase inhibitor.

Description

technical field [0001] The present invention relates to a side effect reducing agent for reducing the side effect of a kinase inhibitor, an anticancer drug comprising a combination of a branched-chain amino acid and a kinase inhibitor, a drug kit thereof, and the like. this application claims priority based on Japanese Patent Application No. 2011-264687 for which it applied to Japan on December 2, 2011, The content is used here. Background technique [0002] Inhibitors of various kinases involved in tumor cell proliferation, angiogenesis, and the like are expected to function as anticancer agents. For example, sorafenib, a kinase inhibitor having inhibitory activity against various kinases in vivo, is clinically used as an anticancer agent for hepatocellular carcinoma and renal cell carcinoma in particular. [0003] On the other hand, many anticancer agents have serious side effects, and depending on the symptoms and severity of the side effects, administration may have to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61K31/44A61K45/00A61P35/00A61P43/00
CPCA61K31/47A61K31/4439A61K31/506A61K31/416A61K31/496A61K31/4365A61K31/5377A61K31/198A61K31/517A61K31/44A61K45/06A61P1/16A61P35/00A61P43/00A61K2300/00
Inventor 山本直树坂井田功
Owner EA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com